Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability

Executive Summary

Study and formulation requirements under PREA mean that interchangeability application might not be much more of a leap.

Advertisement

Related Content

Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel
Interchangeability: FDA Sets ‘Stringent’ Standard On Design Differences
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability
Biosimilar Sponsors May Seek Interchangeability Before FDA Sets Rules
Pediatric Study Waiver, Deferral Determinations Could Harm Approvals, Firms Tell FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel